Traders should monitor the upcoming earnings call on March 17 for potential updates on clinical progress, cash runway, or guidance that could impact valuation, particularly given the lack of approved therapies in the target indications.
Price Chart
Executive Summary
Trevi Therapeutics announced an upcoming conference call to discuss its fourth quarter and full-year 2025 financial results, along with business updates. No financial data was released in this press release, which serves only as a notification of the forthcoming earnings event.
Key Facts
- Trevi Therapeutics will host a conference call on March 17, 2026, at 4:30 p.m. ET to discuss Q4 and full-year 2025 financial results.
- The call will include senior management and will be webcast live; registration is required.
- No financial results or material business updates were disclosed in this release.
- The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough (RCC).
- Haduvio has shown statistically significant reduction in cough frequency in clinical trials but is not yet approved by the FDA.
Financial Impact
No financial data disclosed in this release
Risk Factors
- No financial or operational results are available in this release, limiting immediate trading relevance.
- As a clinical-stage biopharma with no approved products, TRVI remains highly dependent on clinical trial outcomes and regulatory decisions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253310 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | Institutional Cluster | $13.46 $17.26 | ▲ +28.23% | ▲ +23.84% | $14.12 (+4.90%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.46 $17.26 | ▲ +28.23% | ▲ +23.84% | $14.12 (+4.90%) |
Apr 21, 2026 23w ago | DEFA14A | $14.80 $19.07 | ▲ +28.85% | ▲ +24.07% | $14.12 (−4.59%) |
Apr 20, 2026 23w ago | Press Release | $14.62 $17.36 | ▲ +18.74% | ▲ +11.84% | $14.12 (−3.42%) |
Apr 17, 2026 23w ago | 424B5 | $15.40 $18.15 | ▼ −17.82% | ▼ −11.05% | $14.12 (+8.31%) |
Apr 17, 2026 24w ago | 8-K | $15.23 $17.91 | ▼ −17.60% | ▼ −11.45% | $14.12 (+7.29%) |
Apr 17, 2026 24w ago | Press Release | $15.23 $17.91 | ▲ +17.60% | ▲ +11.45% | $14.12 (−7.29%) |
Mar 17, 2026 28w ago | Press Release | $10.69 $13.46 | ▲ +25.91% | ▲ +14.39% | $14.12 (+32.09%) |
Mar 10, 2026 29w ago | Press Release | $11.94 $13.45 | ▲ +12.65% | ▲ +1.12% | $14.12 (+18.26%) |
Mar 9, 2026 29w ago | Press Release | $11.70 $13.50 | ▲ +15.38% | ▲ +3.40% | $14.12 (+20.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access